163 related articles for article (PubMed ID: 37743730)
41. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
[TBL] [Abstract][Full Text] [Related]
42. Alpelisib-Induced Diabetic Ketoacidosis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and Review of the Literature.
Ziegengeist JL; Elmes JB; Strassels SA; Patel JN; Moore DC
Clin Breast Cancer; 2024 Jun; 24(4):e204-e209. PubMed ID: 38245400
[TBL] [Abstract][Full Text] [Related]
43. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
Tsang ES; Aggarwal RR; Dhawan MS; Bergsland EK; Alvarez EA; Calabrese S; Pacaud R; Garcia J; Fattah D; Thomas S; Grabowsky J; Moasser MM; Munster PN
Cancer Res Commun; 2022 Jul; 2(7):570-576. PubMed ID: 36923283
[TBL] [Abstract][Full Text] [Related]
44. Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Wang DG; Barrios DM; Blinder VS; Bromberg JF; Drullinsky PR; Funt SA; Jhaveri KL; Lake DE; Lyons T; Modi S; Razavi P; Sidel M; Traina TA; Vahdat LT; Lacouture ME
Breast Cancer Res Treat; 2020 Aug; 183(1):227-237. PubMed ID: 32613539
[TBL] [Abstract][Full Text] [Related]
45. Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience.
Alaklabi S; Roy AM; Attwood K; George A; O'Connor T; Early A; Levine EG; Gandhi S
Front Oncol; 2022; 12():1012391. PubMed ID: 36338738
[TBL] [Abstract][Full Text] [Related]
46. Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature.
Carrillo M; Rodriguez RM; Walsh CL; Mcgarvey M
AACE Clin Case Rep; 2021; 7(2):127-131. PubMed ID: 34095470
[TBL] [Abstract][Full Text] [Related]
47. Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment.
Raphael A; Salmon-Divon M; Epstein J; Zahavi T; Sonnenblick A; Shachar SS
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292649
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics and Pharmacodynamic of Alpelisib.
Royer B; Kaderbhaï CG; Schmitt A
Clin Pharmacokinet; 2023 Jan; 62(1):45-53. PubMed ID: 36633813
[TBL] [Abstract][Full Text] [Related]
49. Body composition measures as a determinant of Alpelisib related toxicity.
Shachar E; Raphael A; Katz U; Kessner R; Shachar SS
Breast Cancer Res Treat; 2024 Jul; 206(2):369-376. PubMed ID: 38584192
[TBL] [Abstract][Full Text] [Related]
50. Alpelisib-induced hyperglycemia in older patients with breast Cancer: Qualitative findings.
Cook K; Almodallal Y; Martin N; Jatoi A
J Geriatr Oncol; 2021 Sep; 12(7):1114-1117. PubMed ID: 33752998
[TBL] [Abstract][Full Text] [Related]
51. Alpelisib to treat breast cancer.
Copur MS
Drugs Today (Barc); 2020 Jun; 56(6):357-363. PubMed ID: 32525134
[TBL] [Abstract][Full Text] [Related]
52. Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer.
Al Zeyoudi J; El Kebbi I; Al Zaabi F; Hashmi S
Cureus; 2021 Dec; 13(12):e20817. PubMed ID: 35141074
[TBL] [Abstract][Full Text] [Related]
53. ALPELISIB - INDUCED HYPERGLYCEMIA.
Ekanayake PS; Gerwer J; Mccowen K
Acta Endocrinol (Buchar); 2022; 18(1):115-117. PubMed ID: 35975254
[TBL] [Abstract][Full Text] [Related]
54. Diabetic Ketoacidosis With the Use of Alpelisib in a Patient With Metastatic Breast Cancer Without Diabetes.
Polisetty L; Teresa Selvin S; Tan JW
JCEM Case Rep; 2024 Apr; 2(4):luae023. PubMed ID: 38524964
[TBL] [Abstract][Full Text] [Related]
55. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
56. Alpelisib: First Global Approval.
Markham A
Drugs; 2019 Jul; 79(11):1249-1253. PubMed ID: 31256368
[TBL] [Abstract][Full Text] [Related]
57. First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center.
Hester A; Henze F; Travi C; Harbeck N; Wuerstlein R
Breast Care (Basel); 2021 Apr; 16(2):129-134. PubMed ID: 34012367
[TBL] [Abstract][Full Text] [Related]
58. A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.
Rodon J; Curigliano G; Delord JP; Harb W; Azaro A; Han Y; Wilke C; Donnet V; Sellami D; Beck T
Oncotarget; 2018 Aug; 9(60):31709-31718. PubMed ID: 30167089
[TBL] [Abstract][Full Text] [Related]
59. Treating Alpelisib-Induced Hyperinsulinemia in Patients with Advanced Breast Cancer - A Real-Life Experience.
Percik R; Oedegaard Smith C; Leibovici A; Shai A
Biologics; 2023; 17():61-67. PubMed ID: 37163178
[TBL] [Abstract][Full Text] [Related]
60. Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
Hoste G; Slembrouck L; Jongen L; Punie K; Matton T; Vander Borght S; Vanden Bempt I; Menten J; Wildiers H; Floris G; Arteaga C; Neven P
Clin Drug Investig; 2018 Nov; 38(11):1071-1075. PubMed ID: 30187361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
